|
| Exchange Disseminated Time | Marksans Pharma Ltd has informed BSE that the Company has received Certificate of suitability for Ranitidine Hydrochloride drug substance from the European Directorate for the Quality of Medicines and Healthcare (EDQM).
With the grant of this Certificate of Suitability for Ranitidine Hydrochloride drug substance by EDQM, the doors of European markets have opened for access for the Company's API business.
It is a significant achievement as the Company is focusing on the Regulated Market for its growth. Companies recently acquired subsidiary M/s. RelonChem Ltd, also markets Ranitidine formulation into the regulated markets of Europe / U.K.
This Certificate is recognized by 35 signatory states of the European Pharmacopoeia Convention and by the European Union. Other Countries have also chosen to recognize them. This Certificate of Suitability can be used by the manufacturers of pharmaceutical products in their applications for marketing authorization to demonstrate the compliance of the drug substance used with the official monograph of European Pharmacopoeia. |
|
|